Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer

Documenti analoghi

• Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer: A cost-effectiveness analysis
  di: Gengwei Huo, et al.
  Pubblicazione: (2023-02-01)
• First-line tremelimumab plus durvalumab and chemotherapy versus chemotherapy alone for metastatic non-small cell lung cancer: a cost-effectiveness analysis in the United States
  di: Wenjie Liu, et al.
  Pubblicazione: (2023-07-01)
• Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer
  di: Wenjie Liu, et al.
  Pubblicazione: (2024-02-01)
• Cost-effectiveness analysis of dostarlimab plus carboplatin-paclitaxel as first-line treatment for advanced endometrial cancer
  di: Maojin You, et al.
  Pubblicazione: (2023-09-01)
• An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum Refractory Endometrial Cancer
  di: Michele Bartoletti, et al.
  Pubblicazione: (2022-07-01)